Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triamcinolone acetonide plus sucralfate gel to prevent esophageal stricture after large-area ESD
ChiCTR2200066181Phase 4Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of triamcinolone acetonide and sucralfate in Esophageal stricture, Esophageal Squamous Cell Carcinoma (ESCC) and Esophageal epithelial dysplasia (EED) (3 arms), sponsored by Ruijin Hospital. Primary endpoints: Duration of drug retention in the wound, Incidence of mild and severe esophageal stenosis and 1 more. Started Nov 2022; status: recruiting.
02
Drugs
triamcinolone acetonidesucralfate
03
Conditions
Esophageal strictureEsophageal Squamous Cell Carcinoma (ESCC)Esophageal epithelial dysplasia (EED)
Beyond the preview
Go deeper on ChiCTR2200066181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066181.